Teplizumab may delay the onset of T1D in those who are at high risk for the disease.
The ABC News (6/19, Mehta) website reports that “a new drug” called teplizumab “may delay the onset of insulin-dependent” type 1 diabetes (T1D) “in those who are at high risk for the autoimmune disease,” researchers concluded in a randomized study “conducted on people ages eight to 49 at high risk for” T1D. The findings were published in the New England Journal of Medicine. AMA Morning Round 6/20/2019
테플리주맙은 제1형 당뇨병 발병 위험성이 높은 사람들의 발병을 지연시킬 수 있습니다